Comparative Pharmacology
Head-to-head clinical analysis: SPRX 105 versus TURQOZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SPRX 105 versus TURQOZ.
SPRX-105 vs TURQOZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SPRX-105 is a dual dopamine D2 and serotonin 5-HT1A receptor partial agonist, functioning as a postsynaptic antagonist and presynaptic agonist at D2 receptors, and as a partial agonist at 5-HT1A receptors, modulating neurotransmitter release.
TURQOZ is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the synaptic cleft, leading to increased serotonin levels.
SPRX-105 is administered orally at a dose of 50 mg once daily.
400 mg orally once daily.
None Documented
None Documented
12-15 hours in healthy adults; extended to 24-30 hours in renal impairment.
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours) requiring dose adjustment
Primarily renal (70-80% unchanged) with 15-20% biliary/fecal elimination.
Primarily renal (80% unchanged) with 10% fecal, 5% biliary, 5% other
Category C
Category C
Unknown
Unknown